mjn-neuro

Lluís Amat, diseñador gráfico de Fundación Integralia DKV, nos comparte su experiencia sobre inclusión y superación. A lo largo de su vida, Lluís ha enfrentado múltiples desafíos: desde prejuicios en la adolescencia por no beber alcohol hasta dificultades laborales debido a la falta de comprensión sobre su condición. Su primer jefe le dijo que su temblor le impediría trabajar como diseñador gráfico y lo despidió, afectando su autoestima y su confianza profesional. Sin embargo, todo cambió cuando llegó a Fundación Integralia DKV, donde encontró un entorno que valoraba su talento por encima de cualquier limitación. Gracias a este apoyo, recuperó su confianza y pudo demostrar su verdadero potencial como diseñador. Gracias a la Fundación Integralia DKV, Lluís nos comparte con orgullo su mayor aporte: la primera Guía de Inclusión para personas con Epilepsia para Empresas, un recurso clave para ayudar a las organizaciones a ser más inclusivas con personas con epilepsia. A través de esta guía, busca eliminar barreras invisibles, combatir el desconocimiento y fomentar entornos laborales accesibles para todos. 📌 La inclusión no es solo una cuestión de diversidad, sino una oportunidad para construir equipos más fuertes. 🔗https://lnkd.in/dWpgZMhb ¿Qué opinas sobre la importancia de la inclusión en el ámbito laboral? ¡Nos encantaría conocer tu experiencia! 💬 mjn-neuro Fundación Integralia DKV EIT Health

Today, on International Epilepsy Day, we come together to raise awareness and support all people living with this condition. At MJN, we remain committed to delivering effective solutions that improve the quality of life of those who deal with epilepsy on a daily basis. Together, we can make a difference. 💜 #mjn #mjnneuro #innovation #tecnhology #neurociencia #salud #neuroscience #health #research #healthcare

Summary of our participation at the DxPx Conference in Munich! 🇩🇪 This event has been a great opportunity for MJN, where we were able to hold several meetings with potential investors interested in our current funding round for expansion in the United States. 🌎💡 In addition, we have established new relationships with partners and participants of EIT Health programs, strengthening our network and opening up new possibilities for collaboration for the future. We would like to especially thank EIT Health and Aline Noizet, as Venture Manager, for the invitation to this event and for providing us with such valuable connections. 🙌✨ We continue to work to take MJN to the next level! 🚀 #mjn #mjnneuro #innovation #tecnhology #neurociencia #salud #neuroscience #health #research #healthcare #DxPxConference #EITHealth #Innovation #Funding #ExpansionUSA

Promoting innovation with the support of ACCIÓ and the Generalitat de Catalunya We are pleased to announce that our project has been selected within the L1 line of the grant program for open and disruptive innovation projects, awarded by ACCIÓ - Agència per la Competitivitat de l'Empresa de la Generalitat de Catalunya. This funding will allow us to continue improving and evolving our mjn-SERAS device, with the aim of getting closer and closer to our mission: transforming the lives of people with epilepsy through technological innovation. From mjn-neuro, we would like to sincerely thank this support. Collaboration and the promotion of initiatives like this are key to moving towards a future where technology and health go hand in hand. 🔗 For more information about this program, you can visit the following link: #mjn #mjnneuro #innovation #tecnhology #neurociencia #salud #neuroscience #health #research #healthcare

MJN Neuro on its way to the DxPx Conference 2025 in Munich📍 David Blánquez Caurel will attend the DxPx Conference in Munich on January 26 and 27. 🌍✨ This conference, organized in collaboration with EIT Health, is a key event for innovative companies in the health and life sciences sector. It gives us an excellent opportunity to meet with partners and investors interested in our next investment round in 2025, aimed at the expansion of mjn-neuro in the United States. 💡 The DxPx Conference is not only a meeting point for startups and scale-ups, but also a platform to generate strategic connections in the global health ecosystem. We would especially like to thank Venture portfolio manager and EIT Health for their support and collaboration. #mjn #mjnneuro #innovation #tecnhology #neurociencia #salud #neuroscience #health #research #healthcare #epilepsy #epilepsia #cambiosocial #socialchange #impactosocial #neuro #neurologia #research #innovation #healthcare #medicaldevice #ai #artificialintelligence #mjnseras #brain

Découvrez les 29 start-up sélectionnées pour la nouvelle édition du programme EIT Health Catapult ! 🚀 Jusqu'au 15 février, vous pouvez visionner en ligne : - Les pitches de ces start-up demi-finalistes 🎙️ ; - Les sessions de questions / réponses avec le jury. ▶️ Inscrivez-vous ici : https://lnkd.in/exGhN33z Les demi-finalistes sont des start-up européennes prometteuses des secteurs des sciences de la vie et des technologies de la santé. L'objectif du programme ? 🔎 Les aider à développer leurs projets en les mettant en relation avec des experts et investisseurs internationaux. Félicitations aux projets sélectionnés ! Aptadel Therapeutics, ArrayPatch Ltd, Cellectric Biosciences, Fusix Biotech GmbH, Immunofusion, Nūmi, PepKon, PoliRNA, Rejuversen, Urimon onderzoek, Antegenes, BrightComSol, Brightmind.AI, CC Diagnostics, CheckEye, cureVision GmbH, Custom Surgical, FindAir, Galenband, Healshape, Kinetic Cortex, Lifebloom, mjn-neuro, NimBio, NIMBLE Diagnostics, PsyCurio, The Blue Box Biomedical Solutions, Tympany Medical , VitalSigns Oy - #EITHCatapult #HealthTech #LifeSciences #HealthcareInnovation EIT Health France, bioRN Life Science Cluster, Medical Valley EMN e. V., Carlos Cunha, Charles Huot, Julia Morawski, Mélanie P., Dorothea HellerbrandArantxa Encinas-López, Virginie Giraud

Understanding the symptoms of Alzheimer's disease Alzheimer's disease is a devastating condition that profoundly affects sufferers and their loved ones. Over a period of 7 to 15 years from diagnosis, sufferers experience a progressive loss of memory and identity, to a point where the reality around them becomes unrecognizable. The disease leads to a steady increase in dependency and deterioration in quality of life. What are the key symptoms of Alzheimer's? Memory loss: Patients often forget recent events and have difficulty remembering important information. Language problems: They experience difficulty finding words or following a conversation. Difficulty doing simple tasks: Performing everyday tasks becomes increasingly complicated. Disorientation in time and space: sufferers may get lost in familiar places and become disoriented about time and place. Loss of judgement: They have trouble making decisions and evaluating situations adequately. Difficulty in thinking elaborate thoughts: The ability to think and reason in a complex way is affected. Loss of objects: They frequently forget where they have left objects or place them in unusual places. Changes in mood: Emotional changes can be abrupt and unpredictable. Behavioural changes: They may experience alterations in their behaviour and behavioural patterns. Changes in behaviour: They may experience alterations in their behaviour and personality. Loss of initiative: Lack of interest in previously enjoyed activities or projects is common. These symptoms reflect the profound and gradual impact of the disease on daily life. Understanding and ongoing support are essential to manage this disease effectively and to improve the quality of life of those coping with it. #mjn #mjnneuro #innovation #tecnhology  #Alzheimer #research #innovation #dementia #dementiaawareness #dementiaresearch #research #alzheimer #alzheimersdisease #alzheimersawareness #alzheimersresearch #healthcare #medicaldevice #ai #artificialintelligence

Pleased to be selected to pitch in front of investors and partners.

A big step in our regulatory process !!

¡We have obtained CE Marking under the new MDR Regulation!👏 We are proud to announce that our mjn-SERAS device is now CE Marked under the demanding European Union's Medical Device Regulation (MDR). This is a key step in ensuring that we continue to offer safe, effective medical devices that are aligned with the most advanced regulations in the industry. This transition process from the old MDD Regulation to MDR started in 2022 and has been successfully completed this December 2024, thanks to the support and certification of BSI Group. Achieving this certification has not been an easy task: it has required extensive assessment, teamwork, and attention to detail every step of the way. We would like to highlight the incredible work of Fernando Atienza García, PS Consulting and the entire MJN team, who have once again demonstrated their commitment to innovation and excellence in medical devices. This achievement not only marks a milestone in our history, but also reinforces our mission to improve the quality of life of people with epilepsy by ensuring that our products meet the highest standards of quality and safety. Thank you to everyone who has made this possible. 👏 We continue to work with the same dedication to advance the field of neuroscience and health. #mjn #mjnneuro #innovation #tecnhology #neurociencia #salud #neuroscience #health #research #healthcare #epilepsy #epilepsia #cambiosocial #socialchange #impactosocial #neuro #neurologia #research #innovation #healthcare #medicaldevice #ai #artificialintelligence #mjnseras #brain #eumdr